These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16030368)

  • 41. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012.
    Saposnik G; Fonarow GC; Pan W; Liang L; Hernandez AF; Schwamm LH; Smith EE;
    Stroke; 2014 Nov; 45(11):3343-51. PubMed ID: 25300975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
    Teramoto T; Uno K; Miyoshi I; Khan I; Gorcyca K; Sanchez RJ; Yoshida S; Mawatari K; Masaki T; Arai H; Yamashita S
    Atherosclerosis; 2016 Aug; 251():248-254. PubMed ID: 27419905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Appropriate Level of Low-Density Lipoprotein Cholesterol for Secondary Prevention of Coronary Artery Disease.
    Naito R; Miyauchi K; Konishi H; Tsuboi S; Ogita M; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Daida H
    J Atheroscler Thromb; 2016; 23(4):413-21. PubMed ID: 26558399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can group medical clinics improve lipid management in diabetes?
    Crowley MJ; Melnyk SD; Ostroff JL; Fredrickson SK; Jeffreys AS; Coffman CJ; Edelman D
    Am J Med; 2014 Feb; 127(2):145-51. PubMed ID: 24462012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical records.
    García-Gil M; Blanch J; Comas-Cufí M; Daunis-i-Estadella J; Bolíbar B; Martí R; Ponjoan A; Alves-Cabratosa L; Ramos R
    J Clin Lipidol; 2016; 10(1):134-42. PubMed ID: 26892130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2008 May; 28(5):562-9. PubMed ID: 18447654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients.
    Gavish D; Leibovitz E; Elly I; Shargorodsky M; Zimlichman R
    Isr Med Assoc J; 2002 Sep; 4(9):694-7. PubMed ID: 12440233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).
    Malhotra N; Keshan MK; Agarwal A; Kumar RA; Trailokya A; Dalvi K; Talele S
    J Assoc Physicians India; 2016 Apr; 64(4):38-46. PubMed ID: 27734640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents.
    Kim BK; Kim DW; Oh S; Yoon SJ; Park S; Jeon DW; Yang JY
    Coron Artery Dis; 2010 May; 21(3):182-8. PubMed ID: 20168221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
    Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
    Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. The Bogalusa Heart Study.
    Bao W; Srinivasan SR; Wattigney WA; Bao W; Berenson GS
    Arch Intern Med; 1996 Jun; 156(12):1315-20. PubMed ID: 8651840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.
    Asch DA; Troxel AB; Stewart WF; Sequist TD; Jones JB; Hirsch AG; Hoffer K; Zhu J; Wang W; Hodlofski A; Frasch AB; Weiner MG; Finnerty DD; Rosenthal MB; Gangemi K; Volpp KG
    JAMA; 2015 Nov; 314(18):1926-35. PubMed ID: 26547464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.